InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar)

Catalog #SIM0009
Clone:
Atezolizumab
Reactivities:
Human

$217.00 - $7,526.00

$217.00 - $7,526.00

Choose an Option...
  • 100 mg - $7,526.00
  • 50 mg - $4,229.00
  • 25 mg - $2,942.00
  • 5 mg - $843.00
  • 1 mg - $217.00
  • 500 mg+ (Quote Only)
In stock
Only %1 left

Product Details

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Atezolizumab making it ideal for research use. This Atezolizumab biosimilar reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed on T lymphocytes, B lymphocytes, NK cells, dendritic cells, as well as IFNĪ³ stimulated monocytes, epithelial cells and endothelial cells. PD-L1 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L1 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. PD-L1 is thought to play an important role in tumor immune evasion. Induced PD-L1 expression is common in many tumors and results in increased resistance of tumor cells to CD8 T cell mediated lysis. Atezolizumab blocks the interaction of PD-L1 with PD-1 and CD80.

Specifications

Isotype Human IgG1
Recommended Isotype Control(s) RecombiMAb human IgG1 (N297A) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Immunogen Not available or unknown
Reported Applications Flow Cytometry
Western Blot
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <1EU/mg (<0.001EU/Ī¼g)
Determined by LAL gel clotting assay
Sterility 0.2 Āµm filtration
Production Purified from cell culture supernatant
Purification Protein A
RRID AB_2894730
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze.